Andexanet alfa for the reversal of factor Xa inhibitors

Favresse, J; Hardy, M; van Dievoet, MA; Sennesael, AL; Douxfils, J; Samama, CM; Vornicu, O; Dincq, AS; Lessire, S; Mullier, F

Mullier, F (reprint author), CHU UCL Namur, Hematol Lab, Ave G Therasse 1, B-5530 Yvoir, Belgium.

EXPERT OPINION ON BIOLOGICAL THERAPY, 2019; 19 (5): 387

Abstract

Introduction: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索